Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 3Venous Thromboembolism 1Thoracic Neoplasms 1Solid Tumor 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Noonan Syndrome 1Neoplasms by Site 1Neoplasms 1Lung Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Healthy Participants 1Colorectal Neoplasms 1Carcinoma 1Bronchial Neoplasms 1Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation 1

Interventions

Gefitinib 3Erlotinib Hydrochloride 3sotorasib 1pralsetinib 1osimertinib 1ficlatuzumab 1exemestane 1entinostat 1durvalumab 1cobimetinib 1camrelizumab 1Tyrosine Kinase Inhibitors 1Radiosurgery 1Prednisone 1Pemetrexed 1Leuprolide 1Dasatinib 1Carboplatin 1Afatinib 1AZD3759 14-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Respiratory Tract Diseases × sotorasib × Clear all
NCT05054725 2026-01-06

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Revolution Medicines, Inc.

Phase 2 Completed
47 enrolled 17 charts
Thoracic

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Respiratory Tract Diseases, Respiratory Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡